3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 86 points (-0.5%) at 16,084 as of Friday, April 11, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,014 issues advancing vs. 1,941 declining with 158 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include Shire ( SHPG), down 1.5%, and Novo Nordisk A/S ( NVO), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Novartis ( NVS) is one of the companies pushing the Drugs industry lower today. As of noon trading, Novartis is down $0.81 (-1.0%) to $83.02 on average volume. Thus far, 929,559 shares of Novartis exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $82.70-$83.45 after having opened the day at $82.94 as compared to the previous trading day's close of $83.83.

Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. Novartis has a market cap of $203.9 billion and is part of the health care sector. Shares are up 4.3% year-to-date as of the close of trading on Thursday. Currently there are 4 analysts that rate Novartis a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Novartis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Perrigo Company ( PRGO) is down $2.62 (-1.8%) to $141.63 on average volume. Thus far, 717,555 shares of Perrigo Company exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $140.64-$144.49 after having opened the day at $143.00 as compared to the previous trading day's close of $144.25.

Perrigo is buying Canam Care as of Jan 2012 for $36. Perrigo Company has a market cap of $20.0 billion and is part of the health care sector. Shares are down 6.0% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Perrigo Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.36 (-1.2%) to $30.25 on average volume. Thus far, 14.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 28.3 million shares. The stock has ranged in price between $30.16-$30.50 after having opened the day at $30.50 as compared to the previous trading day's close of $30.61.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. Pfizer has a market cap of $199.7 billion and is part of the health care sector. Shares are down 0.1% year-to-date as of the close of trading on Thursday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Dow Plunges on Trade War Worries but Walmart and Verizon Finish Positively

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

Tuesday Turnaround in Politics: Is a Trade War on the Horizon?

FANG Stocks Get Swept Up in Broader Market Selloff

FANG Stocks Get Swept Up in Broader Market Selloff

Snap Shares Plunge After Cowen Cuts Price Target

Snap Shares Plunge After Cowen Cuts Price Target

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders